Hepatitis C is a liver disease caused by hepatitis C virus (HCV) infection, and it accounts for 130-150 million people infected with the disease worldwide. HCV is classified into genotypes (GT) 1-6, and most common GT in Korea is reported as 1b and 2a. Treatment goal of the disease is to achieve sustained virolological response (SVR12) defined as the HCV RNA level below the lower limit of quantification at 12 weeks after the cessation of the therapy. Treatment options include prescription drugs, non-prescription drugs and supplements such as milk thistles and selenium. Direct acting antivirals are main stay of the treatment option although they may fail to show SVR over the extended period of time. Community pharmacists should make every effort to help the patients and care givers monitor therapeutic outcomes and incidences of adverse events during and after the treatment schedule.

Keywords: Hepatitis C virus, Direct acting antivirals, Community pharmacist, Pharmaceutical care service